Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tarperprumig - Alexion Astrazeneca Rare Disease

Next Previous
Drug Profile

Tarperprumig - Alexion Astrazeneca Rare Disease

Alternative Names: ALXN-1820

Latest Information Update: 03 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease
  • Class Anti-inflammatories; Antianaemics; Bispecific antibodies
  • Mechanism of Action Properdin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Discontinued Haematological disorders; Sickle cell anaemia

Most Recent Events

  • 31 Oct 2025 Phase-II clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis (Newly diagnosed) in Canada, South Korea (Parenteral) (NCT07160608)
  • 09 Sep 2025 Alexion Pharmaceuticals plans to initiate a phase II trial for Vasculitis in Argentina, Brazil, Canada, China, France, Germany, Italy, Poland, South Korea, Spain, Taiwan, Turkey and United Kingdom (Parenteral) (NCT07160608)
  • 09 Nov 2023 Discontinued - Phase-I for Haematological disorders (In volunteers) in Australia (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top